drugset
drugset / Trial / NCT03462173

The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects

NCT03462173 ↗

Phase 1 Completed 32 enrolled Sunshine Lake Pharma Co., Ltd.
RandomizedSequentialQuadruple-blindTreatment

Summary

The Safety, Tolerability and Pharmacokinetic Study of Chronic Hepatitis C Treatment Drug Yimitasvir in Healthy Adults Subjects.

Timeline

Start
2014-12-03
Primary completion
2015-01-30
Completion
2016-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Yimitasvir Small molecule 30 mg Oral
Subject Yimitasvir Small molecule 100 mg Oral
Subject Yimitasvir Small molecule 200 mg Oral
Subject Yimitasvir Small molecule 400 mg Oral
Subject Yimitasvir Small molecule 600 mg Oral
Subject Yimitasvir Small molecule 800 mg Oral
Subject Yimitasvir Small molecule 1000 mg Oral

Indications

chronic hepatitis C virus infection